Pyrimidine Derivatives Targeting Multiple RTK Pathways
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments often face challenges with drug resistance and non-selective targeting of cancer cells, leading to inadequate efficacy and increased side effects, highlighting the need for targeted therapies that can selectively eliminate subpopulations of cells involved in tumour survival and progression.
Innovation Solution
Development of novel pyrimidine derivatives with specific antiproliferative activity, which can be used in pharmaceutical compositions to target and inhibit key pathways involved in cancer cell proliferation, offering a selective approach to treating proliferative diseases like cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer chemotherapy is used, then cancer cells are eliminated, but drug resistance develops and side effects increase
Solution Approach 1:
The patent segments the cancer treatment approach by developing pyrimidine derivatives that can simultaneously target multiple RTK pathways (EGFR, HER2, VEGFR, etc.) rather than using single-target agents. This multi-pathway inhibition strategy divides the complex cancer signaling network into manageable targetable units, improving treatment efficacy while reducing the development of drug resistance through multiple mechanisms of action
Solution Approach 2:
The pyrimidine compounds described in the patent exhibit multi-functionality by acting as dual inhibitors of both tyrosine kinase and tubulin. This universal approach allows a single agent to interfere with multiple RTK pathways and microtubule function simultaneously, addressing the limitation of single-target therapies and reducing the emergence of resistance while maintaining treatment efficacy
2Adaptability or versatility
If single target RTK inhibitors are used, then specific pathways are blocked, but alternative pathways activate causing resistance
Solution Approach 1:
The patent merges multiple therapeutic functions into a single pyrimidine derivative molecule that can inhibit multiple RTK pathways (EGFR, HER2, VEGFR, PDGFR, etc.) simultaneously. This combination approach within a single molecular framework prevents cancer cells from activating alternative resistance pathways, as multiple critical signaling routes are blocked concurrently, thereby maintaining long-term treatment effectiveness
3Productivity
If non-selective chemotherapy agents are used, then cancer cells are attacked, but healthy cells are also damaged
Solution Approach 1:
The pyrimidine derivatives described in the patent exhibit local quality through their selective targeting mechanism. The compounds demonstrate preferential activity against cancer cells by specifically inhibiting oncogenic RTK pathways and tubulin functions that are dysregulated in cancer, while showing sparser activity against normal cells. This selective toxicity approach eliminates cancer cells efficiently while minimizing damage to healthy tissues
Data Source
AI summary
The invention provides novel pyrimidine derivatives of formula I, to methods of preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for using such compounds in treatment of diseases including cancer; wherein R1, R2, R3, R4, R5, L, A, D, E, Z, and Y are as defined in the specification.